Navigation Links
Tengion Provides Business Update and Reports Second Quarter 2011 Financial Results
Date:8/9/2011

EAST NORRITON, Pa., Aug. 9, 2011 /PRNewswire/ -- Tengion, Inc. (Nasdaq: TNGN) today provided a business update and reported its financial results for the second quarter ended June 30, 2011.

"This is an important time for Tengion as we continue to make progress on our lead clinical and preclinical programs, as well as on our corporate and partnership strategy," said David Scheer, chairman of the Tengion board of directors. "Our search for a new chief executive officer is underway and our dialogue with the FDA is ongoing as we continue to advance our Neo-Urinary Conduit clinical trial. We expect to provide more updates in the near term as we execute on our overall strategy."

Neo-Urinary Conduit Bladder Cancer Trial – Clinical UpdateTengion is currently conducting an initial clinical trial of its lead product candidate, the Neo-Urinary Conduit™, for use in bladder cancer patients requiring a urinary diversion following bladder removal (cystectomy).  The Neo-Urinary Conduit is a combination of a patient's own cells and bioabsorbable scaffold that is intended to catalyze regeneration of a native bladder tissue conduit, passively transporting urine from the ureters through a stoma, or hole in the abdomen, into a standard ostomy bag.  Patients requiring some form of urinary diversion with today's standard of care, the use of a segment of bowel tissue to construct a conduit for urine to exit from the body into an ostomy bag, are at risk of complications associated with the use of bowel tissue as well as those associated with the surgery to harvest the bowel tissue.

The trial is designed to assess the safety and preliminary efficacy of the Neo-Urinary Conduit, as well as to allow the clinical investigators to optimize the surgical procedure and post-surgical care by incorporating the outcomes observed in each patient into the surgical approach f
'/>"/>

SOURCE Tengion, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related biology technology :

1. Tengion Announces Leadership Transition
2. Tengion Provides Business Update and Reports First Quarter 2011 Financial Results
3. Tengion to Host Conference Call to Provide a Business Update and Report First Quarter 2011 Financial Results on May 12, 2011
4. Tengion Announces Addition of Two Renal Experts to Research & Development Advisors Panel
5. Tengion To Host Conference Call To Provide a Business Update and Report Fourth Quarter 2010 Financial Results on March 25, 2011
6. Tengion Announces Pricing of $31.4 Million Private Placement
7. Tengion Addresses Recent Trading Activity in its Common Stock
8. Tengion to Present at the 13th Annual BIO CEO & Investor Conference and the Leerink Swann Hot Topics in Therapeutics Roundtable Conference
9. Tengion Presents New Large Animal Data Demonstrating Functional Kidney Regeneration at the American Society for Transplantation Annual Conference
10. Tengion Appoints Richard E. Kuntz, MD to its Board of Directors
11. Tengion Announces Webcast of Analyst and Investor Meeting on October 27, 2010
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/1/2014)... 2014 The participants committed to not ... spending their own time adjusting, tweaking and testing virtual ... were ready for judging. , “I enjoyed being involved ... leader. “The entries showed a commendable range exploring ... of the print medium and the creativity of the ...
(Date:10/1/2014)... September 30, 2014 In response ... tools to address sales, training and consumer engagement ... developed innovative mobile applications to turn their clients’ ... agency’s latest customized mobile app creations, are now ... , In partnership with Toyota, StudioPMG created a ...
(Date:10/1/2014)... Award winning unified communications (UC) and ... collaboration bundles that combine next generation communication technologies. ... for low, flat rate fees. With four ... optimized solutions to meet their technology needs. , ... minutes (1K, 5K, 10K increments) or audio minutes ...
(Date:10/1/2014)... 2014 TeselaGen Biotechnology has ... to expand their bioCAD/CAM software suite, which uses ... The Small Business Innovation Research Phase II grant will ... exclusive license from the Lawrence Berkeley National Laboratory. j5 ... an LBNL laboratory that develops alternative fuel technologies for ...
Breaking Biology Technology:Array Architects Challenges Staff to Create with 3D Printer 2Digital Agency Studio PMG Launches New Case Studies on Website 2SoundConnect Launches New Audio, Web and Video Bundles 2TeselaGen Receives $750k NSF SBIR Phase II Award 2TeselaGen Receives $750k NSF SBIR Phase II Award 3
... 10 Bioheart, Inc., (OTC Bulletin Board: BHRT) a company ... diagnose and treat heart failure and other cardiovascular diseases announced ... development has been invited to participate in the 2009 World ... , Ms. Comella will speak on the concurrent ...
... , , , ... , Current studies show that only four ... point of care. By 2019, the Congressional Budget Office (CBO) estimates ... to about 90 percent , EHRs will create ...
... ATLANTA and LONDON, Sept. 10 CryoLife ... device and cardiovascular tissue processing company, today announced the first clinical ... received CE mark approval in August 2009. BioFoam was used in ... to promote hemostasis (a complex process that stops bleeding) by sealing ...
Cached Biology Technology:Bioheart Inc. to Participate in the 2009 World Stem Cell Summit on September 23rd 2Bioheart Inc. to Participate in the 2009 World Stem Cell Summit on September 23rd 3Greenway Medical Technologies Plays Leading Role in Interoperability Demonstrations at Seventh Annual Public Health Information Network (PHIN) Conference 2Greenway Medical Technologies Plays Leading Role in Interoperability Demonstrations at Seventh Annual Public Health Information Network (PHIN) Conference 3Greenway Medical Technologies Plays Leading Role in Interoperability Demonstrations at Seventh Annual Public Health Information Network (PHIN) Conference 4CryoLife Announces First Clinical Use of BioFoam(R) 2CryoLife Announces First Clinical Use of BioFoam(R) 3CryoLife Announces First Clinical Use of BioFoam(R) 4CryoLife Announces First Clinical Use of BioFoam(R) 5
(Date:9/30/2014)... LIVERMORE, Calif. The National Institutes of Health ... grant today to develop an electrode array system ... the brain works through unprecedented resolution and scale. ... efforts to support President Obama,s BRAIN (Brain ... new research effort to revolutionize our understanding of ...
(Date:9/30/2014)... of Medicine reports positive results of a phase ... subset of lung cancer marked by rearrangement of the ... with advanced non-small cell lung cancer testing positive for ... with 3 complete responses and 33 partial responses. Median ... disease to resume its growth after being slowed by ...
(Date:9/30/2014)... using marijuana, new research, involving mice and published in ... of Leukocyte Biology , suggests that just because ... That,s because a team of Italian scientists have found ... damage to the immune system. This damage may result ... multiple sclerosis, inflammatory bowel disease and rheumatoid arthritis in ...
Breaking Biology News(10 mins):NIH taps lab to develop sophisticated electrode array system to monitor brain act 2NIH taps lab to develop sophisticated electrode array system to monitor brain act 3NEJM: Crizotinib effective in Phase 1 trial against ROS1 lung cancer 2Adolescent exposure to thc may cause immune systems to go up in smoke 2
... Advanced Iris Recognition Algorithm Detects and Compensates for ... ... Neurotechnology today,announced the addition of VeriEye iris recognition technology ... products. VeriEye SDK features an advanced iris recognition,algorithm that ...
... Stanley, Inc. (NYSE:,SXE), a leading provider of ... government, announced today that it has entered into ... an,engineering, intelligence operations and information technology services,company. The ... cash,subject to certain working capital and other adjustments ...
... AMBER Alert Safety Centers,Inc. announced today that the Company ... Fair, to be held at the Meadowlands Sport,Complex in East ... the entire family featuring rides, free entertainment, games, exhibits,shopping and ... Patterson -- Chief Executive Officer ...
Cached Biology News:New VeriEye SDK from Neurotechnology Enables Development of Reliable, Cost-effective Biometric Iris Recognition Systems 2New VeriEye SDK from Neurotechnology Enables Development of Reliable, Cost-effective Biometric Iris Recognition Systems 3Stanley to Acquire Oberon Associates 2Stanley to Acquire Oberon Associates 3Stanley to Acquire Oberon Associates 4AMBER Alert Safety Centers to Provide Child Safety Precautions at the New Jersey State Fair at the Meadowlands 2AMBER Alert Safety Centers to Provide Child Safety Precautions at the New Jersey State Fair at the Meadowlands 3
... tissue extracts (liver, kidney, spleen, and heart) and ... It was also tested with microsomal fractions prepared ... simple and reliable method for measuring NDPase activity ... the inorganic phosphate released from NDP by the ...
... Principle: The sulfidoleukotrienes ... are products of arachidonic acid ... In the past, they were ... of Anaphylaxis (SRS-A)". They are ...
... the condition in which a lack of ... the various antioxidants. Oxidative stress appears ... several diseases, including artherosclerosis, chronic inflammatory diseases, ... antioxidant systems that are very important for ...
... Compound(s) tested through 63 ... assays spanning a broad ... panel includes many non ... several non-selective assays. ...
Biology Products: